HuGAL-FR21 is a humanized monoclonal IgG1 antibody targeting FGFR2IIIb. It effectively blocks the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibits FGF-induced phosphorylation of FGFR2IIIb. Additionally, HuGAL-FR21 reduces FGFR2 expression in SNU-16 cells and demonstrates significant antitumor activity in gastric cancer xenograft models in nude mice. This compound is valuable for research in cancers such as gastric cancer.
Target:
FGFR
* VAT and and shipping costs not included. Errors and price changes excepted